Ever since health officials announced Canada’s first known case of rare, post-vaccination blood clots back in April, scientists have been racing to learn more about what causes the potentially deadly condition — and how to treat it.

Now, a team from McMaster University in Hamilton has published new research-backed recommendations calling on clinicians to use a combination of two treatments: anti-clotting drugs alongside high doses of an intravenous, antibody-based therapy.

The potential effectiveness was outlined in three case studies featuring some of the first Canadian patients who developed post-vaccine blood clots, which was published Wednesday in The New England Journal of Medicine.

The three